OptiRTP Joins Japan New Zealand Business Council
OptiRTP has joined the Japan New Zealand Business Council (JNZBC), a network of New Zealand and Japanese organisations focused on bilateral trade and business relationships.
The membership supports OptiRTP’s preparation for planned market entry into Japan from 2027. The JNZBC provides connections to experienced Japan-connected businesses and resources for companies navigating the Japanese market.
CEO Jon Doherty has prior experience in Japan, having served as CEO of Tokyo-based Daijob, Inc from 2002 to 2006. He also helped facilitate the establishment of the NZ Travel Cafe in Tokyo in 2006 and initiated the Time Out in New Zealand program following the 2011 Tohoku earthquake.
OptiRTP has identified Japan’s focus on active aging and quality of life improvement as aligned with its therapeutic platform’s applications.
About OptiRTP
OptiRTP (Return to Play) is a New Zealand-based biotech company. Its core technology, OBST (Optimum Bio Sound Therapy), has 352,000+ documented therapy hours with zero serious adverse events reported. OBST is an FDA-registered Class I medical device, 510(k)-exempt (registration and listing, not FDA clearance or approval), that uses dynamic, patterned acoustic neuromodulation via the auditory pathway, with a proposed mechanism involving modulation of central autonomic regulatory networks associated with sleep, pain, recovery and stress regulation. Drug-free and non-invasive, used passively during sleep or rest through a tablet and earbuds. Users can follow recovery markers on their own wearable.
